Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Leblanc

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Transplantation and Cellular Therapy|November 5, 2022
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHDJean-Sébastien Claveau, Richard LeBlanc, Imran Ahmad, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter TransformationMathias Castonguay, Marie-France Gagnon, Alexandre Le Nguyen, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell TransplantRichard LeBlanc, Stéphanie Thiant, Rafik Terra, et al.
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Haematologica|March 26, 2026
Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicityGaspard Jadot, Anna Sabouret, Anne Couture, et al.
Haematologica|October 14, 2021
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysisMarcelo Capra, Thomas Martin, Philippe Moreau, et al.
Blood|June 21, 2003
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaLaurence Catley, Ellen Weisberg, Yu-Tzu Tai, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
Transplantation and Cellular Therapy|October 17, 2024
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma PatientsJean Roy, Sandra Cohen, Guy Sauvageau, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Transplantation and Cellular Therapy|November 5, 2022
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHDJean-Sébastien Claveau, Richard LeBlanc, Imran Ahmad, et al.
Current Oncology (Toronto, Ont.)|October 28, 2025
From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter TransformationMathias Castonguay, Marie-France Gagnon, Alexandre Le Nguyen, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell TransplantRichard LeBlanc, Stéphanie Thiant, Rafik Terra, et al.
British Journal of Haematology|February 9, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group databaseVictor H Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, et al.
Haematologica|March 26, 2026
Tumor flare pain reaction following bispecific T-Cell engagers in multiple myeloma: a unique and underrecognized toxicityGaspard Jadot, Anna Sabouret, Anne Couture, et al.
Haematologica|October 14, 2021
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysisMarcelo Capra, Thomas Martin, Philippe Moreau, et al.
Blood|June 21, 2003
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaLaurence Catley, Ellen Weisberg, Yu-Tzu Tai, et al.
Cancer Research|September 5, 2002
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine modelRichard LeBlanc, Laurence P Catley, Teru Hideshima, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
Transplantation and Cellular Therapy|October 17, 2024
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma PatientsJean Roy, Sandra Cohen, Guy Sauvageau, et al.
Pageof 12